FAPI-Guided Radiotherapy With Cadonilimab and Standard Chemotherapy for Colorectal Peritoneal Metastasis: A Phase III Randomized Controlled Trial (TORHC-PM02)

FAPI-Guided Radiotherapy With Cadonilimab and Standard Chemotherapy for Colorectal Peritoneal Metastasis: A Phase III Randomized Controlled Trial (TORHC-PM02) is a phase 3, randomised interventional study registered as NCT07815834 by Fudan University, with a registry enrolment figure of 198 participants, started 2026-09-01 and due to reach its primary completion in 2030-08-01. Interventions recorded: Second-Line Chemotherapy; Radiation Therapy; Cadonilimab (AK104). Conditions listed: Colon Rectal Cancer Adenocarcinoma; Peritoneal (Metastatic) Cancer; Second-line Treatment; Radiation Therapy; Immunotherapy. Primary outcome: Progression-Free Survival (PFS). Colorectal eligibility wording from the registry: "Histopathologically confirmed colorectal adenocarcinoma". Sites: China. No results are recorded here; the registry entry is the source.